RESEARCH Open Access



Moderating effects of insomnia on the association between urinary phthalate metabolites and depressive symptoms in Chinese college students: focus on gender differences

Tingting $Li^{1\dagger}$, Shuman $Tao^{2,3,4\dagger}$, Tangjun $Jiang^1$, Wanyu Che^1 , Liwei $Zou^{3,4}$, Yajuan $Yang^6$, Fangbiao $Tao^{1,3,4,5*}$ and $Xiaoyan Wu^{1,3,4,5*}$

Abstract

Objectives To investigate the rates of depressive symptoms in college students, explore the relationship between urinary phthalate metabolites and depressive symptoms and their gender differences, and further explore the moderating role of insomnia in this association.

Methods A total of 1 179 college students were recruited from 2 universities in Hefei and Shangrao cities from April to May 2019. The depressive symptoms and insomnia of college students were investigated by the Patient Health Questionnaire 9 and Insomnia Severity Index. The high-performance liquid chromatography-tandem mass spectrometry was adapted to determine the concentration of urinary phthalate metabolites. The generalized linear model was used to analyze the relationship of phthalate metabolites with depressive symptoms. Moderating analysis was used to examine whether insomnia moderated the relationship of phthalate metabolites with depressive symptoms.

Results The rates of mild depression, and moderate depression and above in college students were 31.9% and 9.2%, respectively. The phthalate metabolites exhibited a median and mean concentration spanning from $2.98 \sim 156.55$ ng/mL and $6.12 \sim 205.53$ ng/mL. The generalized linear model results showed that monobutyl phthalate (MBP) (β =1.160, 95%*Cl*: 0.423 ~ 1.896) and low molecular weight phthalate (LMWP) (β =1.230, 95%*Cl*: 0.348 ~ 2.113) were positively correlated with depressive symptoms, and MBP (β =1.320, 95%*Cl*: 0.453 ~ 2.187) and LMWP (β =1.396, 95%*Cl*: 0.351 ~ 2.440) were positively correlated with depressive symptoms only in female college students after stratified by

[†]Tingting Li and Shuman Tao are co-first authors.

*Correspondence: Fangbiao Tao taofangbiao@126.com Xiaoyan Wu xywu@ahmu.edu.cn

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material deviate from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Li et al. BMC Public Health (2025) 25:802 Page 2 of 16

gender. Furthermore, insomnia has a positive moderating role between MBP, LMWP, and depressive symptoms and has a sex-based difference.

Conclusions This study suggests that there is a positive association of phthalate metabolites with depressive symptoms among Chinese college students, as well as insomnia plays a positive moderating role in this association.

Keywords Phthalate metabolites, Depressive symptoms, Insomnia, College students

Introduction

College students are in a critical period of transitioning from adolescence to adulthood. Due to the decrease in social support, the change in social roles, and the increase in pressure, college students are more prone to developing depressive symptoms and other mental health problems [1]. A systematic review and meta-analysis of the rates of depressive symptoms among university students showed that the prevalence of depressive symptoms among university students was between 2.9% and 71.0% from 2009 to 2018, with a overall prevalence of 24.4% [2]. Another systematic review and meta-analysis on the incidence of depressive symptoms among Chinese university students revealed an approximate prevalence rate of 28.4% among this population [3]. Furthermore, in 2019, as the COVID-19 pandemic spread globally, it adversely affected the mental health of university students, leading to a heightened incidence of depression [4]. A metaanalysis revealed that the pooled incidence of depressive symptoms among university students worldwide during the COVID-19 pandemic was 34.0% [5]. These studies show that college students are at high-risk group for the occurrence of depressive symptoms. At present, various risk factors contributing to depressive symptoms among college students have been identified, such as sleep problems [6], insufficient physical activity [7], adverse childhood experiences [8] and so on. Meanwhile, more and more evidence suggests that phthalate exposure is associated with depressive symptoms [9, 10].

Phthalates, a class of widely employed non-persistent chemicals, serve as plasticizers to make several materials with temperature tolerance, malleability, and flexibility [11]. According to the different lengths of the carbon chain, phthalates are categorized into two distinct groups: high-molecular-weight phthalates and low-molecularweight phthalates [12]. Exposure to high-molecularweight phthalate compounds predominantly arises from dietary sources, while the presence of low-molecularweight phthalate metabolites in the body can be attributed to diverse origins, including indoor air exposure, dust inhalation, and the use of personal care products [13]. Since phthalates exist in many consumer products, they frequently escape into the environment, elevating human exposure levels [14]. Human biomonitoring studies collect urine samples to evaluate phthalate exposure in individuals, given that the majority of metabolites of phthalate are eliminated through urine within a 48-hour period [15]. Interestingly, human biomonitoring studies have shown the presence of phthalates in urine samples across all age groups, and with females exhibiting higher concentrations than males [16]. In part, due to female using more personal care products and cosmetics, and therefore an increased susceptibility to skin phthalate exposure [15, 17]. This finding underscores the potential for a gender disparity in both the exposure to and the health impacts of phthalates on individuals [18].

Animal studies have revealed that phthalates exposure can affect brain development, alter the formation of the hippocampal, as well as lead to changes in emotions and behavior [12]. Furthermore, phthalates exposure not only disrupts glutamate and glutamine homeostasis, as well as glutamatergic neurotransmission activity in mice, inducing depressive behaviors [19], but also impairs the hypothalamic-pituitary-thyroid axis balance in rats, causing a decrease in serum thyroid hormone levels, which have been associated with psychological and behavioral problems [20]. For example, a study on mice showed that phthalate exposure can result in depression-like behavior and increase oxidative stress within the brain [21]. Similarly, another study on mice has uncovered that perinatal exposure to phthalates can have transgenerational effects, resulting in the manifestation of depression-like behaviors in the offspring [22]. In addition, a Korean study on the elderly revealed an association between elevated levels of specific phthalate metabolites and a heightened risk of developing depressive symptoms [23]. A United States study on general adults likewise revealed a positive correlation between certain phthalate metabolites and depressive symptoms [10]. Due to phthalates have reproductive toxicity similar to estrogen and antiandrogens [23]. Consequently, the occurrence of depressive symptoms may also be linked to the hormonal disruptions caused by phthalate exposure, given that the brain can be regulated by hormonal signals [24].

Previous research has already revealed the relationship of phthalate exposure with sleep problems [25, 26]. For instance, a study in the United States on females aged 20–39 found that phthalate exposure may increase their risk of developing sleep problems [27]. Similarly, another study using data from the 2005–2010 National Health and Nutrition Examination Survey cycle found that higher concentrations of several phthalate metabolites

Li et al. BMC Public Health (2025) 25:802 Page 3 of 16

in urine among adolescents were associated with shorter sleep duration [28]. Animal studies have indicated that phthalates can disrupt the circadian rhythms of zebrafish, resulting in behavioral changes, increased daytime sleep, and reduced sleep latency [29]. Moreover, phthalates may disrupt neural circuits and hinder the maturation of hormone-mediated mechanisms essential for regulating sleep [30]. Specifically, phthalates have been linked to disrupting progesterone, cortisol, estrogen, and testosterone, all critical hormones regulating sleep [31]. At the same time, some research have suggested that sleep problems are also a significant predictor of the onset of depressive symptoms [31, 32]. Studies have demonstrated that insomnia can interfere with the brain's limbic circuits' ability to adapt at nighttime and resolve emotional distress at nighttime, thereby increasing the risk of developing mental disorders [33]. For example, a study on students from 4 universities in Yunnan province, China, found that insomnia was positively associated with depressive symptoms [34]. Another study on United States college students also found that compared to normal sleep, insomnia was associated with more depressive symptoms [35]. However, whether sleep issues play an important role in the correlation of phthalate exposure with depressive symptoms remains to be further investigated.

Therefore, to address these gaps, we conducted an epidemiological investigation to examine the association between phthalate metabolites, insomnia, and depressive symptoms among Chinese college students. The objectives of this study are threefold: (a) to investigate the rates of depressive symptoms in Chinese college students, (b) to examine the correlation of phthalate metabolites with depressive symptoms in Chinese college students and their gender differences, and (c) to further explore the moderating role of insomnia in the correlation of phthalate metabolites with depressive symptoms.

Methods

Participants

This survey was conducted in 2 universities in Shangrao, Jiangxi Province and Hefei, Anhui Province, China from April to May 2019. Firstly, a normal university in Shangrao City and a medical university in Hefei City were selected by convenient sampling. Subsequently, chemistry major and sports major in normal university, as well as public health major and nursing major in medical universities were selected by stratified cluster sampling. Finally, a comprehensive survey of all freshmen in these majors was conducted. Screening for depression among college freshmen could help identify students at risk for depression, thereby enhancing the development and implementation of targeted preventive interventions [36]. In the present study, a total of 1 179 freshmen were

involved, 1 135 freshmen completed the questionnaire, and 1 012 freshmen provided urine samples for phthalate metabolites analysis. Before conducting the survey, all freshmen were given a unique code. Then, after matching the questionnaire data with urine sample data according to the freshmen' unique codes, the final data comprised 903 valid cases. The average age of the 903 freshmen surveyed was 18.7 years (SD = 1.2), and 31.6% (285/903) were male. The inclusion criteria were as follows: providing written informed consent; submitting a valid questionnaire; providing valid urine samples; no clinically diagnosed mental illness. The inclusion criteria in the analysis were as follows: both data of questionnaire and urinary phthalate metabolites were valid. Exclusion criteria: all participants who do not meet the above inclusion criteria are excluded.

Procedures

In this study, freshman gathered in a classroom and completed an electronic questionnaire utilizing their smartphones. The process generally lasted between $10 \sim 20$ min after the investigators introduces the objectives of the investigation, and principles of anonymity, confidentiality, and voluntary participation. Upon finishing the questionnaire, each freshmen willingly submitted a morning urine sample, which was gathered in a 15 mL polypropylene tube for subsequent analysis. The urine samples underwent centrifugation at a speed of 3500 revolutions per minute for a duration of 10 min, following which the supernatant was extracted and stored in a polypropylene cryotube for further processing. The urine samples were temporarily stored in a -20 $^{\circ}$ C refrigerator for 1 ~ 2 week and long-term frozen in a -80 $^{\circ}\mathrm{C}$ refrigerator in the laboratory of Anhui Medical University until analysis. The Ethics Committee of Anhui Medical University approved this study (NO: 20170291). All participants provided written informed consent prior to their involvement.

Sample size calculation

To determine the sample size, we used the evidence that approximately 28.4% of Chinese college students experience depressive symptoms [3]. We utilized the formula $S = Z^2 \times P \times (1-P)/M^2$ (Z = 1.96, representing the standard normal deviate for a 95% confidence level; P = 28.4%, reflecting the proportion of students with depressive symptoms; M = 0.05, denoting a 5% margin of error) to calculate a sample size was 312 [37]. Consequently, the sample size of 903 college students for this study was fully met.

Questionnaire survey data

A questionnaire was utilized to collect information, encompassing age, gender, height, weight, major (public health, nursing, chemistry, sports), residence area (rural,

Li et al. BMC Public Health (2025) 25:802 Page 4 of 16

urban), number of siblings $(0, \ge 1)$, family economy status, monthly living expenses, learning burden, academic performance, number of friends, parental education level, bodily form, physical activity level, sleep quality, smoking, drinking, family history of depression, family accidents, hospitalization experiences, insomnia, and depressive symptoms.

Family economy was evaluated through the question: "How do you perceive your family's economic condition compared to other students?" The answers were reclassified as "high", "medium" and "low". Monthly living expenses (Yuan) were categorized as "<1 000", "1 000~1 500", "1 501 ~ 2 000", and "> 2 000". To assess learning burden, participants were asked: "How much burden do you feel by studying recently?" The answers were categorized as "much", "some", and "a little". Academic performance was assessed by asking: "How do you think your academic performance is in your class?" Responses were recoded into "poor", "average", and "good". Number of friends was reclassified as " $0 \sim 2$ ", " $3 \sim 5$ ", and " ≥ 6 " [38]. The parental education level was recoded into "senior high school and above", "middle school", and "primary school and below". Bodily form was assessed by asking: "What type of body do you think you have?" The answers were recoded as "thin", "medium", and "fat".

Body mass index (BMI) was calculated by dividing weight by the square of height. Based on Chinese standards, college students aged 18 and above were categorized into four weight statuses: underweight (<18.5 kg/m²), normal weight (18.5 to 23.9 kg/m²), overweight (24.0 to 27.9 kg/m²), and obesity (\geq 28.0 kg/m²) [39]. For college students under 18 years of age, BMI percentiles were used to determine their weight status and were classified into four categories: underweight (BMI < 5th percentile), normal weight (5th- \leq BMI < 85th percentile), overweight (85th- \leq BMI < 95th percentile), and obesity (BMI \geq 95th percentile) [40].

The International Physical Activity Questionnaire Short Form (IPAQ-SF) was used to assess the physical activity levels of college students in the past week [41]. Total physical activity was computed by metabolic equivalents (METs) \times hour/week. Subsequently, physical activity was categorized into three levels: low, middle, and high [42].

College students' sleep quality over the past month was assessed utilizing the Pittsburgh Sleep Quality Index (PSQI) [43]. The score range of the scale is 0 to 21, where a score of ≥8 signifies poor sleep quality, whereas a score of <8 indicates good sleep quality [44]. The PSQI has been verified among Chinese college students and has demonstrated good validity and reliability [44].

Current smoking and alcohol use of college student were assessed using the Young Risk Behavior Surveillance System questionnaire [45]. Smoking status was determined by the question: "In the past month, how many days did you smoke at least one cigarette per day?" Similarly, alcohol use was evaluated by asking: "In the past month, how many days did you have at least one drink per day?" Responses of "<1 day" were considered as "no", whereas responses of "≥1 day" were deemed as "yes".

Family history of depression was assessed by asking "Do you have a family history of depression (i.e., one or more family members including father, mother, or siblings have been diagnosed with depression)?" Family accidents was assessed by asking "In the last year, have you experienced a family accidents (such as divorce of parents)?" Hospitalization was assessed by asking "Have you been hospitalized in the last year (e.g., sick, injured, etc.)?" Responses were categorized as "yes" and "no".

The Insomnia Severity Index (ISI) was adopted to measure the insomnia symptoms of college students in the past two weeks [46]. The ISI is a self-reported measurement designed to evaluate the extent of insomnia severity. The measure comprises 7 distinct items, yielding a total score that spans from 0 to 28. The higher the score, the more severe the insomnia is considered to be. A score of ≥ 9 is indicative of insomnia, while a score of < 9 signifies no insomnia. The ISI has been verified in the Chinese populations, demonstrating robust reliability and validity [47].

College students' depressive symptoms over the past month were assessed using the Patient Health Questionnaire 9 (PHQ-9) [48]. The PHQ-9 is a questionnaire with 9 items, and each item is scored from $0 \sim 3$ using the Likert scale. The score range of the scale is 0 to 27, where higher scores serve as an indicator of more severe depressive symptoms. A score of ≤ 4 indicates no depression, whereas a score ranging from 5 to 9 indicates mild depression, and a score of ≥ 10 indicates moderate depression and above. The PHQ-9 has undergone validation in the Chinese population, demonstrating its robust validity and reliability in accurately assessing depressive symptoms [49].

Urinary phthalate metabolites analysis

Our prior reports have detailed the procedures employed for the analysis of urinary phthalate metabolites [12]. Briefly, we used high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) (6410LC-MS, Agilent Technologies Co., Santa Clara, CA, USA) to analyze 6 phthalate metabolites, including monobutyl phthalate (MBP), monoethyl phthalate (MEP), monomethyl phthalate (MMP), mono-2-ethylhexyl phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP). Furthermore, in this study, the method used by Zota et al. was used to calculate the concentration of high molecular weight phthalate (HMWP)

Li et al. BMC Public Health (2025) 25:802 Page 5 of 16

metabolites and low molecular weight phthalate (LMWP) metabolites [50, 51]. HMWP were equal to the sum of the molar concentrations of MEHP, MEHHP, and MEOHP. LMWP were equal to the sum of the molar concentrations of MBP, MEP, and MMP.

Covariates

In this study, variables with statistically significant difference in the detection rate of depressive symptoms in college student were used as covariates (Table 1). Thus, confounding factors controlled for in this study included age, major, academic performance, number of friends, paternal education level, self-rated bodily form, sleep quality, smoking, drinking, family history of depression, and hospitalization experiences.

Statistical analysis

In this research, when the concentrations of urinary phthalate metabolites were below the limits of detection (LOD), it was substituted with a value calculated as the LOD divided by the square root of 2 [52]. We employed urine specific gravity (SG) to correct the individual urinary phthalate metabolite concentrations to account for variations in urine dilution among individuals [53]. All of the SG-calibrated concentrations were subsequently transformed into log-10.

All statistical analyses were carried out utilizing SPSS 23.0 software. Categorical variables were presented as frequency (percentages) and continuous variables were reported as mean ± standard deviation. The measured non-normal distribution was represented by the median and interquartile range. The chi-square test was adopted to compare the prevalence of depressive symptoms in college students. Pearson correlations between phthalate metabolites, insomnia, and depressive symptoms were calculated. The generalized linear model was adopted to determine the relationship between urinary phthalate metabolites, insomnia, and depressive symptoms. We calculated β value and 95% confidence intervals (95%*CI*) for the explanatory factors, with adjustments made for potential confounding factors. Utilizing the PROCESS plug-in within SPSS software, we conducted an analysis to examine the moderating role of insomnia on the correlation of phthalate metabolites with depressive symptoms. Within the PROCESS plug-in, model 1 was chosen and the confidence interval was set to 95%. Prior to conducting the moderation analyses, we employed mean centering to mitigate multicollinearity. A two-tailed Pvalue < 0.05 was considered statistically significant.

Results

Distribution of depressive symptoms among college students

In this research, the rates of mild depression, and moderate depression and above among college students was 31.9% and 9.2%, respectively. The prevalence of moderate depression and above in college students was sport majors > chemistry majors > public health majors > nursing majors (P < 0.05). The prevalence of moderate depression and above in college students whose number of friends was $0 \sim 2$ was higher than that of college students whose number of friends was $3 \sim 5$, ≥ 6 (P < 0.05). The prevalence of moderate depression and above in students whose father's education level was primary school and below was higher than that of students whose father's education level was middle school, senior high school and above (P < 0.05). The prevalence of moderate depression and above of college students with a poor academic performance, fat bodily form, poor sleep quality, smoking, drinking, family history of depression, hospitalization, and insomnia was higher than that in those with a average or good academic performance, medium or thin bodily form, good sleep quality, no smoking, no drinking, no family history of depression, no hospitalization, and no insomnia (P < 0.05). However, there was no statistically significant difference in other variables (P > 0.05). As shown in Table 1.

Distribution of phthalate metabolites concentration and SG-calibrateds concentration among college students

In this study, MBP, MEP, MMP, MEHP, MEHHP, and MEOHP of the college students were detected in 99.6%, 99.1%, 98.3%, 79.2%, 99.6%, and 99.7%, respectively. Table 2 displays the distribution of urinary phthalate metabolites concentration, along with their respective SG-calibrated concentration. The SG-standardized concentrations (median) of MBP, MEP, MMP, MEHP, MEHHP, MEOHP, LMWP, and HMWP were 123.71 ng/ mL, 17.62 ng/mL, 10.20 ng/mL, 2.98 ng/mL, 14.63 ng/ mL, 8.88 ng/mL, 156.55 ng/mL, and 26.11 ng/mL, respectively. According to gender and further stratified analysis, in male college students, the SG-standardized concentrations (median) of MBP, MEP, MMP, MEHP, MEHHP, MEOHP, LMWP, and HMWP were 131.24 ng/mL, 15.75 ng/mL, 10.24 ng/mL, 3.06 ng/mL, 14.26 ng/mL, 8.73 ng/ mL, 162.42 ng/mL, and 25.59 ng/mL, respectively. In female college students, the SG-standardized concentrations (median) of MBP, MEP, MMP, MEHP, MEHHP, MEOHP, LMWP, and HMWP were 119.05 ng/mL, 18.69 ng/mL, 10.09 ng/mL, 2.88 ng/mL, 14.94 ng/mL, 8.91 ng/ mL, 153.93 ng/mL, and 26.72 ng/mL, respectively.

Li et al. BMC Public Health (2025) 25:802 Page 6 of 16

 Table 1
 Distribution of depressive symptoms in college students

Variable	n (%)		Depressive	symptoms	χ² value	P value
		No depression	Mild depression	Moderate depression and above		
Gender					1.54	0.463
Male	285(31.6)	167(58.6)	87(30.5)	31(10.9)		
Female	618(68.4)	365(59.1)	201(32.5)	52(8.4)		
Major					14.76	0.022
Public health	223(24.7)	146(65.5)	61(27.4)	16(7.1)		
Nursing	326(36.1)	193(59.2)	112(34.4)	21(6.4)		
Chemistry	178(19.7)	99(55.6)	58(32.6)	21(11.8)		
Sports	176(19.5)	94(53.4)	57(32.4)	25(14.2)		
Residential area					5.97	0.051
Rural	497(55.0)	276(55.5)	175(35.2)	46(9.3)		
Urban	406(45.0)	256(63.1)	113(27.8)	37(9.1)		
Number of siblings		,			0.33	0.848
0	228(25.2)	138(60.5)	70(30.7)	20(8.8)		
≥ 1	675(74.8)	394(58.4)	218(32.3)	63(9.3)		
Self-reported family economy	((/	(-:-)	6.17	0.187
Low	204(22.6)	110(53.9)	71(34.8)	23(11.3)	0.17	0.107
Medium	645(71.4)	384(59.5)	206(31.9)	55(8.6)		
High	54(6.0)	38(70.4)	11(20.4)	5(9.2)		
Monthly living expenses (Yuan)	34(0.0)	30(70.4)	11(20.4)	3(3.2)	8.75	0.188
< 1000	181(20.0)	105(58.0)	61(33.7)	15(8.3)	0.73	0.100
1000~1500	565(62.6)	323(57.2)	189(33.5)	53(9.3)		
			, ,			
1501 ~ 2000	119(13.2)	78(65.5)	32(26.9)	9(7.6)		
>2000	38(4.2)	26(68.4)	6(15.8)	6(15.8)	0.24	0.000
Self-reported learning burden	1.4/1.6\	0(64.2)	2/21 4)	2(4.4.2)	8.34	0.080
A little	14(1.6)	9(64.3)	3(21.4)	2(14.3)		
Some	545(60.4)	340(62.4)	159(29.2)	46(8.4)		
Much	344(38.0)	183(53.2)	126(36.6)	35(10.2)		
Self-reported academic performance				- ()	19.75	0.001
Good	167(18.5)	101(60.5)	58(34.7)	8(4.8)		
Average	557(61.7)	331(59.4)	182(32.7)	44(7.9)		
Poor	179(19.8)	100(55.9)	48(26.8)	31(17.3)		
Number of friends					19.14	0.001
0~2	101(11.2)	43(42.6)	45(44.6)	13(12.8)		
3~5	247(27.4)	135(54.7)	84(34.0)	28(11.3)		
≥6	555(61.4)	354(63.8)	159(28.6)	42(7.6)		
Paternal education level					16.35	0.003
Primary school and below	191(21.2)	100(52.4)	63(33.0)	28(14.6)		
Middle school	434(48.1)	247(56.9)	151(34.8)	36(8.3)		
Senior high school and above	278(30.7)	185(66.5)	74(26.6)	19(6.8)		
Maternal education level					8.62	0.071
Primary school and below	393(43.5)	220(56.0)	129(32.8)	44(11.2)		
Middle school	316(35.0)	183(57.9)	109(34.5)	24(7.6)		
Senior high school and above	194(21.5)	129(66.5)	50(25.8)	15(7.7)		
Self-rated bodily form					13.45	0.009
Thin	225(24.9)	133(59.1)	72(32.0)	20(8.9)		
Medium	417(46.2)	265(63.5)	124(29.7)	28(6.8)		
Fat	261(28.9)	134(51.3)	92(35.2)	35(13.5)		
BMI groups	(====)	- (/	V		8.93	0.178
Underweight	150(16.6)	84(56.0)	51(34.0)	15(10.0)	-	-
Normal weight	662(73.3)	400(60.4)	205(31.0)	57(8.6)		
Overweight	72(8.0)	39(54.2)	27(37.5)	6(8.3)		
Obesity	19(2.1)	9(47.4)	5(26.3)	5(26.3)		

Li et al. BMC Public Health (2025) 25:802 Page 7 of 16

Table 1 (continued)

	n (%)		Depressive	symptoms	χ² value	Pvalue
		No depression	Mild depression	Moderate depression and above		
Physical activity level					7.88	0.096
Low	131(14.5)	69(52.7)	44(33.6)	18(13.7)		
Medium	469(51.9)	290(61.8)	146(31.1)	33(7.1)		
High	303(33.6)	173(57.1)	98(32.3)	32(10.6)		
Sleep quality					137.55	< 0.001
Good	798(88.4)	514(64.4)	239(29.9)	45(5.7)		
Poor	105(11.6)	18(17.1)	49(46.7)	38(36.2)		
Smoking					24.65	< 0.001
Yes	53(5.9)	25(47.2)	13(24.5)	15(28.3)		
No	850(94.1)	507(59.6)	275(32.4)	68(8.0)		
Drinking					16.36	< 0.001
Yes	184(20.4)	89(48.4)	66(35.9)	29(15.7)		
No	719(79.6)	443(61.6)	222(30.9)	54(7.5)		
Family history of depression					15.59	< 0.001
Yes	32(3.5)	12(37.5)	11(34.4)	9(28.1)		
No	871(96.5)	520(59.7)	277(31.8)	74(8.5)		
Family accidents					1.19	0.551
Yes	115(12.7)	63(54.8)	39(33.9)	13(11.3)		
No	788(87.3)	469(59.5)	249(31.6)	70(8.9)		
Hospitalization					8.05	0.018
Yes	95(10.5)	48(50.5)	31(32.6)	16(16.9)		
No	808(89.5)	484(59.9)	257(31.8)	67(8.3)		
Insomnia					217.14	< 0.001
Yes	119(13.2)	13(10.9)	57(47.9)	49(41.2)		
No	784(86.8)	519(66.2)	231(29.5)	34(4.3)		

Pearson correlations between phthalate metabolites, insomnia, and depressive symptoms

Pearson coefficients of correlation between phthalate metabolites, insomnia, and depressive symptoms were presented in the heatmap (Figs. 1, 2 and 3) and Table S1. The MBP (r=0.097, P<0.05), LMWP (r=0.084, P<0.05), and insomnia (r=0.671, P<0.01) were positively correlated with depressive symptoms. According to gender and further stratified analysis, in female college students, the MBP (r=0.130, P<0.01), LMWP (r=0.112, P<0.05), and insomnia (r=0.618, P<0.01) were positively correlated with depressive symptom, while only insomnia (r=0.761, P<0.01) was positively correlated with depressive symptoms among male college students.

Association between phthalate metabolites, insomnia, and depressive symptoms by adjusted generalized linear model

After controlling for age, major, self-reported academic performance, number of friends, paternal education level, self-rated bodily form, sleep quality, smoking, drinking, family history of depression, and hospitalization, the generalized linear model results showed that MBP (β = 1.160, 95%*CI*: 0.423 ~ 1.896), LMWP (β = 1.230, 95%*CI*: 0.348 ~ 2.113), and insomnia (β = 0.656, 95%*CI*: 0.597 ~ 0.716) were positively correlated with depressive

symptoms. According to gender and further stratified analysis, in female college students, the generalized linear model results showed that MBP (β =1.320, 95%CI: 0.453 ~ 2.187), LMWP (β =1.396, 95%CI: 0.351 ~ 2.440), insomnia (β =0.608, 95%CI: 0.532 ~ 0.684) were positively correlated with depressive symptoms. In male college students, the generalized linear model results showed that only insomnia (β =0.745, 95%CI: 0.645 ~ 0.845) was positively correlated with depressive symptoms (Table 3).

Moderating effects of insomnia on the correlation of phthalate metabolites with depressive symptoms

After controlling for confounding factors, the moderating effects analysis revealed that insomnia had positive moderating effects between MBP, MEHP, LMWP, and depressive symptoms, with respective β values for the interaction terms of 0.21, 0.08, and 0.23. According to gender and further stratified analysis, in male college students, insomnia positively moderated the relationships between MEP, MMP, LMWP, and depressive symptoms, with respective β values for the interaction terms of 0.26, 0.43, and 0.27. In female college students, insomnia positively moderated the relationships between MBP, MEHHP, and depressive symptoms, with respective β values for the interaction terms of 0.22 and 0.20. As shown in Table 4.

 Table 2
 Distribution of phthalate metabolites concentration and SG-calibrateds concentration in college students

MRP Uncalibrated SSEAF-14256 SRP 100 35th 50th 75th 90th 75th 90th 75th 90th 75th 90th 75th 90th 75th 80th 75th 80th 75th 80th 75th 80th 75th 80th 90th 90th 75th 90th	Gender	Phthalate metaholite	Concentration (ng/ml)				Percentiles) di				Detected (%)	rvalue	Pyaliie
Wigh Unclinated 173-84-1649 37-88 47.28 69.88 115.45 31.48 44.44 99.6 0.08 Wigh Conclination 177-34-164 42.28 32.28 90.0 113.7 148.7 44.44 99.6 0.08 Wigh Uncollinated 340-8-65.1 42.8 68.8 32.8 77.2 32.9 32.7 32.8 93.7 0.08 Wigh Uncollinated 326-11.18 37.9 5.6 72.8 32.9 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 60.5 12.2 32.8 40.8 60.8 32.8 40.8 60.8 32.8 40.8 60.8 40.8 60.8 60.8 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2				mean±SD	5th	10th	25th	50th	75th	90th	95th			
WEP Uncalibrated 17,11 Act Modes 47,8 35,9 18,9 18,2 34,9 34,	Overall	MBP	Uncalibrated	158.36±143.36	37.48	47.80	69.88	115.45	195.77	314.87	444.43	9.66	98.0	< 0.001
With Uncalibrated 36.046-561.2 3.72 5.49 162.2 341.2 70.73 99.1 10.2 70.2 99.1 10.2 70.2 99.1 10.2 39.2 99.2 10.2 39.2 99.3 99.2 99			SG-calibrated	171.74±166.49	40.48	52.38	79.60	123.71	205.93	342.84	492.43			
MAPP Socialization 58,612-64 1, 48 6,08 996 1552 80,21 33,93 99,93 99,93 MAPP Uscalibrated 1132/±1188 2,79 5,89 158,9 22,21 32,85 99,9 10,90 MAPP Uscalibrated 1132/±1188 2,9 5,90 5,10 0,10 0,23 28,9 6,10 32,2		MEP	Uncalibrated	34.09±65.62	3.72	5.30	8.99	16.82	34.12	70.79	120.23	1.66	0.92	< 0.001
MMP Uncalibated 12321+11289 244 355 586 956 1545 2345 958 050 050 050 050 051 050 051 050 051 050 051 050 051 050			SG-calibrated	36.40±64.11	4.98	90.9	96.6	17.62	35.28	80.12	139.91			
MEHP Uncelibrated 1371+118 3.79 5.08 7.18 10.20 15.41 22.21 32.45 7.25 10.20 15.41 22.21 32.45 7.25 9.89 10.20 10.20 10.20 10.20 10.20 20.20 10.20		MMP	Uncalibrated	12.95±12.99	2.41	3.55	5.86	9.95	15.95	24.47	32.85	98.3	98.0	< 0.001
MEHP Uncalibrated 565-1832 0.10 0.51 2.80 6.75 10.26 155.3 79.2 0.96 MEHP Uncalibrated 6.12+12.46 4.91 0.91 0.93 2.84 6.75 11.03 18.95 0.96 0.98 MEHP Uncalibrated 2.56+6.74 3.91 8.92 1.88 1.93 5.95 9.95 0.89 0.98 </td <td></td> <td></td> <td>SG-calibrated</td> <td>13.21±11.88</td> <td>3.79</td> <td>5.08</td> <td>7.18</td> <td>10.20</td> <td>15.41</td> <td>23.21</td> <td>32.45</td> <td></td> <td></td> <td></td>			SG-calibrated	13.21±11.88	3.79	5.08	7.18	10.20	15.41	23.21	32.45			
MEHHP Uscalibated 51241561 0.09 0.11 6.29 6.15 11.03 181.9 9.06 0.09 0.11 6.29 6.15 11.03 181.9 9.06 0.09 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02<		MEHP	Uncalibrated	5.65±18.32	0.10	0.10	0.51	2.80	6.26	10.26	15.53	79.2	96:0	< 0.001
WEHHP Uncalibated 2516±7243 451 59 134 2245 371 371 370 306 084 WEHHP Uncalibated 256±6131 453 539 531 514 424 375 370 369 97 084 WEHR Uncalibated 1520±3369 363 514 447 3273 370 369 97 083 LAMP Uncalibated 1520±3369 362 440 610 888 1386 279 369 97 083 HAMP Uncalibated 1520±3369 362 17,2 1247 325 370 654 960 98 1386 1386 138 364 98 1386 138 364 98 138 364 98 138 364 98 138 364 98 138 364 98 138 364 98 98 98 98 98 98 98 98			SG-calibrated	6.12 ± 15.61	60.0	0.11	0.59	2.98	6.15	11.03	18.19			
MCOMP Uncalibated 1500+3504 5.56 + 6.10 1.25		MEHHP	Uncalibrated	25.16±72.43	4.51	5.91	8.79	13.81	22.45	37.11	57.01	9.66	0.84	< 0.001
MECHP Uncalibrated 1497±3977 266 363 511 842 1356 2220 3559 997 083 LAWP Uncalibrated 1520±3369 302 440 610 884 1396 229 997 083 HWWP Uncalibrated 2053±18519 322 712 1043 1525 4070 6595 1080 - 083 HWWP Uncalibrated 4654±10401 1042 1252 4276 6595 1080 - 083 MBP Uncalibrated 4654±10401 424 125 125 4070 6599 11724 4070 6599 1080 997 083 MBP Uncalibrated 1370±1030 328 426 772 1421 744 1576 3041 6699 11724 990 993 993 990 993 990 990 990 990 990 990 990 990 990 990 9			SG-calibrated	25.64±61.31	5.53	6.79	82.6	14.63	22.91	40.56	64.08			
MAMP		MEOHP	Uncalibrated	14.97±39.77	2.96	3.63	5.51	8.42	13.56	22.20	35.59	2.66	0.83	< 0.001
MAMP			SG-calibrated	15.20±33.69	3.63	4.40	6.10	8.88	13.98	23.69	39.82			
HAWP Uncalibrated 205.53+1819 5829 7152 10343 15655 24798 39575 51490 10551 HAWP Uncalibrated 4570±10811 1043 1256 1023 2525 4070 6595 10201 10204 10551 MBP Uncalibrated 183.08±155.74 4638 5709 863.2 14213 218.73 216.04 457.25 4000 4		LMWP	Uncalibrated	190.97±156.91	50.20	61.41	94.21	147.24	233.76	370.90	498.05	ı	0.85	< 0.001
HMWP Uncalibated 4570±12800 842 1072 1653 2525 4070 6505 10801 - 0.033 MBP Uncalibated 46.45±10811 1043 12.56 1828 26.11 41.73 72.46 11.049 996 0.995 MBP Uncalibated 17.075±14043 4382 5790 88.75 131.24 21.869 31.694 457.52 MMP Uncalibated 13.24±931 443 51.7 174 13.58 36.93 98.9 0.95 MEHP Uncalibated 13.24±931 443 51.7 172 172 174 135.8 98.9 0.93 MEHP Uncalibated 13.24±931 443 51.7 172 172 174 135.8 98.9 0.93 MEHP Uncalibated 23.24±630 0.08 0.11 1.26 3.06 6.34 11.67 2.19 85.6 0.98 MEHP Uncalibated 23.3±64.39 51.7 168 32.6 6.2 11.90 21.9 85.6 0.98 MEHP Uncalibated 19.27±46.01 3.8 4.2 12.6 18.8 18.8 13.8 13.8 3.9 99.9 0.91 MEHP Uncalibated 19.27±46.01 3.8 4.2 12.6 18.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8			SG-calibrated	205.53±185.19	58.29	71.52	103.43	156.55	247.98	395.75	514.90			
MBP Uncabbated 4645±10811 10.43 1.25 18.28 26.11 41.73 72.46 112.04 MEP Uncabbated 170.75±140811 10.43 1.25 18.21 2.81.3 46.05 99.6 0.92 MEP Uncabbated 170.75±14081 4.62 5.60 9.28 17.55 31.64 450.6 99.6 0.92 MEP Uncabbated 32.93±6687 4.42 5.71 9.16 15.75 24.6 30.31 98.9 0.93 MEH Uncabbated 1235±94 4.42 5.71 9.16 15.75 24.6 30.31 98.9 0.93 MEHP Uncabbated 7.69±21.4 0.10 1.12 1.02 1.16 3.05 9.85 1.19 3.05 9.85 0.93 0.93 0.93 0.93 1.17 4.43 0.94 1.15 3.45 3.45 3.15 3.15 3.15 3.15 3.15 3.15 3.25 3.25 3.25		HMWP	Uncalibrated	45.70 ± 128.00	8.42	10.72	16.53	25.25	40.70	65.95	108.01	1	0.83	< 0.001
MBP Uncalibated 18308±15574 4638 57.09 68.22 142.13 218.73 4606 906 906 909 909 MEP Uncalibrated 18707±14043 43.82 51.95 81.75 13.24 43.82 67.92 17.85 13.84 457.52 9.09 <td></td> <td></td> <td>SG-calibrated</td> <td>46.45 ± 108.11</td> <td>10.43</td> <td>12.56</td> <td>18.28</td> <td>26.11</td> <td>41.73</td> <td>72.46</td> <td>112.04</td> <td></td> <td></td> <td></td>			SG-calibrated	46.45 ± 108.11	10.43	12.56	18.28	26.11	41.73	72.46	112.04			
MEP Uncalibated 17075±14043 4382 5195 81.75 131.24 21369 316.94 4575 MMP Uncalibated 38.16±2.84 402 560 9.28 1765 31.18 71.44 135.88 98.9 0.95 MMP Uncalibrated 12.33±9.91 4.42 5.12 1.15 1.94 5.52 0.98 0.91 MEHP Uncalibrated 1.33±9.91 4.43 5.12 1.12 1.94 5.52 0.99 0.91 MEHP Uncalibrated 5.69±1.10 0.10 1.14 3.35 6.82 1.15 2.40 9.05 0.98 MEHP Uncalibrated 5.9±16.00 0.08 0.11 1.26 3.06 6.34 1.16 2.03 9.84 9.05 0.98 MEHP Uncalibrated 5.9±16.00 0.8 0.11 1.26 3.06 6.34 1.16 2.15 4.41 6.04 3.24 4.41 6.04 8.34 6.04 <td>Male</td> <td>MBP</td> <td>Uncalibrated</td> <td>183.08 ± 155.74</td> <td>46.38</td> <td>57.09</td> <td>86.32</td> <td>142.13</td> <td>218.73</td> <td>356.73</td> <td>460.06</td> <td>9.66</td> <td>0.92</td> <td>< 0.001</td>	Male	MBP	Uncalibrated	183.08 ± 155.74	46.38	57.09	86.32	142.13	218.73	356.73	460.06	9.66	0.92	< 0.001
MEP Uncalibated 3816±9284 402 560 928 1755 31.18 71.44 13588 989 0.95 MMP SG-calibrated 32.93±6687 442 5.71 916 1757 2426 90.91 1777 MEHP Uncalibrated 13.25±9.91 443 5.12 712 174 13.62 243 55.94 1077 MEHP Uncalibrated 6.95±1.14 0.10 0.11 1.26 3.06 6.34 1.167 24.03 6.96 MEHP Uncalibrated 29.5±1.00 0.08 0.11 1.26 3.06 6.34 1.167 24.03 6.96 MEHP Uncalibrated 29.37±64.39 5.71 6.68 9.92 1.46 5.75 3.08 6.94 9.79 0.91 MEMP Uncalibrated 19.02±45.01 3.3 4.41 6.44 6.41 80.72 3.04 4.94 4.11 1.102 1.15 1.15 4.43 6.11			SG-calibrated	170.75 ± 140.43	43.82	51.95	81.75	131.24	213.69	316.94	457.52			
MMP Uncalibrated 32.93±6.687 442 5.71 9.16 15.75 2947 6969 117.77 MEHP Uncalibrated 13.70±10.30 3.86 465 7.22 11.27 1742 24.26 30.31 98.9 0.91 MEHP Uncalibrated 769±21.14 0.10 0.11 1.26 3.05 6.34 11.57 24.26 30.31 98.9 0.91 MEHP Uncalibrated 6.95±16.00 0.08 0.11 1.26 3.05 4.64 80.72 99.6 0.91 MEOHP Uncalibrated 19.27±46.01 3.8 4.32 6.36 94.3 15.26 254.1 41.37 99.6 0.91 LMWP Uncalibrated 19.27±46.01 3.8 4.32 6.36 94.3 15.26 254.1 41.37 99.6 0.91 LMWP Uncalibrated 19.00±4.175.92 57.24 75.08 104.18 23.7 25.06 4.7 0.90 MBP		MEP	Uncalibrated	38.16 ± 92.84	4.02	2.60	9.28	17.65	31.18	71.44	135.88	6.86	0.95	< 0.001
MMP Uncalibrated 1370±1030 336 465 722 1127 1742 2426 3031 989 091 SG-calibrated 1235±991 443 512 712 1024 15.15 1943 25.2 MEHP Uncalibrated 56±16,00 0.00 0.11 1.26 3.06 6.34 11.67 24.03 9.09 0.98 MEHP Uncalibrated 293±6439 5.71 1.26 3.06 6.34 11.67 24.03 9.95 0.91 MEHP Uncalibrated 293±6439 5.71 6.68 9.43 1.56 26.15 46.44 80.72 9.96 0.91 MEOHP Uncalibrated 1922±6401 3.88 4.32 6.36 9.43 13.85 45.45 9.96 0.91 LMMP Uncalibrated 16.90±35.36 3.44 4.41 6.04 8.73 13.85 4.54 8.74 8.74 8.74 8.74 8.74 9.74 9.94			SG-calibrated	32.93±66.87	4.42	5.71	9.16	15.75	29.47	69.69	117.77			
MEHP Uncalibrated 1235±991 443 5.12 7.12 10.24 15.15 1943 25.52 MEHP Uncalibrated 766±21.14 0.10 0.10 1.14 335 682 1190 22.19 856 0.98 MEHP Uncalibrated 3356±84.72 5.37 7.15 10.28 15.62 26.53 986 0.91 MEHP Uncalibrated 1927±64.03 5.71 6.36 14.26 26.53 986 0.91 MEOHP Uncalibrated 1927±64.03 3.74 4.41 6.04 873 1381 2385 45.26 0.91 LMWP Uncalibrated 1806±175.92 5.74 75.08 110.17 180.98 257.42 39.58 47.97 36.98 47.94 0.91 MMP Uncalibrated 50.01±14.96.9 9.4 12.61 18.40 28.12 47.97 36.98 47.94 0.91 MEP Uncalibrated 50.44±113.93 9.54 <		MMP	Uncalibrated	13.70±10.30	3.36	4.65	7.22	11.27	17.42	24.26	30.31	6.86	0.91	< 0.001
MEHP Uncalibrated 7.69±21.14 0.10 0.11 1.14 3.35 6.82 11.90 22.19 85.6 0.98 SG-calibrated 6.95±16.00 0.08 0.11 1.26 3.06 6.34 11.67 24.03 9.06 0.91 MEHHP Uncalibrated 29.3±64.39 5.71 6.68 9.92 14.26 22.55 39.85 85.20 0.91 0.91 MEOHP Uncalibrated 19.27±66.01 3.38 4.32 6.36 9.43 15.26 25.41 41.37 9.96 0.91 LMWP Uncalibrated 19.27±66.01 3.38 4.32 6.36 19.3 15.26 25.41 41.37 9.96 0.91 HMWP Uncalibrated 10.90±175.92 57.24 55.49 10.41 10.47 10.47 39.37 30.49 47.41 80.47 30.90 47.43 10.49 95.5 95.60 99.5 95.60 99.50 99.50 99.50 99.60 9			SG-calibrated	12.35±9.91	4.43	5.12	7.12	10.24	15.15	19.43	25.52			
MEHHP Uncalibrated 6.95±16.00 0.08 0.11 1.26 3.06 6.34 11.67 24.03 9.09 0.91 MEHHP Uncalibrated 33.56±84.72 5.37 7.15 10.28 15.62 26.15 46.44 80.72 99.6 0.91 MEOHP Uncalibrated 19.27±46.01 3.38 4.32 6.36 94.3 15.26 25.41 41.37 99.6 0.91 LMWP Uncalibrated 16.90±35.36 3.44 4.41 6.04 87.3 13.81 23.85 45.4 0.91 HMWP Uncalibrated 200.14±147.72 56.94 68.39 104.18 16.24 24.73 13.78 47.94 9.75 9.96 0.91 MBP Uncalibrated 60.11±149.69 9.54 12.51 18.40 28.76 47.19 83.71 143.58 71.73 143.58 71.73 143.58 71.73 143.58 9.54 12.51 18.40 80.04 12.71 18.40		MEHP	Uncalibrated	7.69±21.14	0.10	0.10	1.14	3.35	6.82	11.90	22.19	85.6	0.98	< 0.001
MEHHP Uncalibrated 33.56±84.72 5.7 7.15 10.28 15.62 26.15 46.44 80.72 99.6 0.91 SG-calibrated 29.37±64.39 5.71 6.68 99.2 14.26 25.5 39.85 85.20 0.91 9.96 0.91 MEOHP Uncalibrated 19.27±6.01 3.38 4.32 6.36 9.43 15.26 25.41 41.37 99.6 0.91 LMWP Uncalibrated 16.90±35.36 3.4 4.41 6.04 8.73 13.81 23.85 44.54 0.90 0.91 LMWP Uncalibrated 20.01±147.72 56.94 68.39 104.18 16.24 24.97 35.08 47.94 0.91 0.91 MBP Uncalibrated 60.11±14969 9.84 12.51 18.71 25.59 42.43 17.32 14.36 0.95 0.90 0.91 MBP Uncalibrated 14.697±135.89 35.78 44.05 64.70 10.50 17.30			SG-calibrated	6.95 ± 16.00	0.08	0.11	1.26	3.06	6.34	11.67	24.03			
MEOHP Uncalibrated 1927±64.39 5.71 6.68 992 1426 2555 39.85 85.20 MEOHP Uncalibrated 19.27±46.01 3.38 4.32 6.36 943 15.26 25.41 41.37 99.6 0.91 LMWP Uncalibrated 16.90±35.36 3.44 4.41 6.04 8.73 1381 23.85 44.54 0.91 0.91 LMWP Uncalibrated 218.06±175.92 57.24 57.84 110.17 180.98 25.42 38.79 47.99 9.97 0.90 MBP Uncalibrated 60.1±149.69 9.84 12.61 18.40 28.16 47.19 83.31 13.58 - 0.90 MBP Uncalibrated 60.1±149.69 9.84 12.55 18.71 25.90 4.43 41.36 9.5 0.90 - 0.90 MBP Uncalibrated 146.97±13.53 35.9 5.79 17.30 31.64 419.40 99.5 0.91		MEHHP	Uncalibrated	33.56±84.72	5.37	7.15	10.28	15.62	26.15	46.44	80.72	9.66	0.91	< 0.001
MEOHP Uncalibrated 19.27±46.01 3.38 4.32 6.36 9.43 15.26 25.41 41.37 99.6 0.91 LMWP Uncalibrated 16.90±35.36 3.44 4.41 6.04 8.73 13.81 23.85 44.54 0.91 LMWP Uncalibrated 21.80€±175.92 57.24 75.08 110.17 180.98 257.42 393.72 52.06 - 0.91 HMWP Uncalibrated 60.11±149.69 9.84 12.61 1840 28.76 47.19 83.31 137.80 - 0.91 MBP Uncalibrated 146.97±13.93 9.54 12.55 18.71 25.59 42.43 71.73 143.58 - 0.90 MBP Uncalibrated 172.19±177.32 39.64 53.59 73.26 47.94 47.94 99.5 0.91 MEP Uncalibrated 172.19±177.32 35.5 73.4 16.51 34.88 70.92 11.541 99.5 0.91			SG-calibrated	29.37±64.39	5.71	89.9	9.92	14.26	22.55	39.85	85.20			
LMWP Uncalibrated 16.90±35.36 3.44 4.41 6.04 8.73 13.81 23.85 44.54 LMWP Uncalibrated 218.06±175.92 57.24 75.08 110.17 180.98 257.42 393.72 522.06 - 0.91 HMWP SG-calibrated 200.14±147.72 56.94 68.39 104.18 162.42 249.77 350.98 479.49 - 0.90 HMWP Uncalibrated 52.64±113.93 9.54 12.55 18.71 25.59 42.43 71.73 143.58 - 0.90 MBP Uncalibrated 146.97±135.89 35.78 44.05 64.70 105.00 173.09 312.64 419.40 99.5 0.91 MEP Uncalibrated 172.19±177.32 35.5 78.36 119.05 200.04 360.82 495.64 29.5 MEP Uncalibrated 12.0±148.12 3.55 5.7 8.71 16.51 34.88 70.92 115.41 99.2 0.91		MEOHP	Uncalibrated	19.27±46.01	3.38	4.32	6.36	9.43	15.26	25.41	41.37	9.66	0.91	< 0.001
LMWP Uncalibrated 218.06±175.92 57.24 75.08 110.17 180.98 257.42 393.72 522.06 - 0.91 HMWP SG-calibrated 200.14±147.72 56.94 68.39 104.18 162.42 249.77 350.98 479.49 - 0.90 HMWP Uncalibrated 52.64±113.93 9.54 12.61 18.40 28.16 47.19 83.31 137.80 - 0.90 MBP Uncalibrated 146.97±135.89 35.78 44.05 64.70 105.00 173.09 312.64 419.40 99.5 0.84 MEP Uncalibrated 172.19±177.32 35.6 5.79 8.71 16.51 34.88 70.92 115.41 99.2 0.91 MEP Uncalibrated 12.60±14.06 2.03 3.76 83.16 37.64 83.16 147.93 8.71 0.91 MMP Uncalibrated 12.60±14.06 2.03 37.64 83.16 37.64 83.16 98.1			SG-calibrated	16.90±35.36	3.44	4.41	6.04	8.73	13.81	23.85	44.54			
SG-calibrated 200.14±147.72 56.94 68.39 104.18 162.42 249.77 350.98 479.49 - 0.00 Uncalibrated 60.11±1496.9 9.84 12.61 18.40 28.16 47.19 83.31 137.80 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00		LMWP	Uncalibrated	218.06±175.92	57.24	75.08	110.17	180.98	257.42	393.72	522.06	1	0.91	< 0.001
HMWP Uncalibrated 60.11±149.69 9.84 12.61 18.40 28.16 47.19 83.31 137.80 - 0.90 SG-calibrated 52.64±113.93 9.54 12.55 18.71 25.59 42.43 71.73 143.58 - 0.90 MBP Uncalibrated 146.97±135.89 35.78 44.05 64.70 105.00 173.09 312.64 419.40 99.5 0.84 MEP Uncalibrated 32.21±48.12 3.55 5.07 8.71 16.51 34.88 70.92 115.41 99.2 0.91 MMP Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.91 MMP Uncalibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.57 36.15 98.1 0.84			SG-calibrated	200.14 ± 147.72	56.94	68.39	104.18	162.42	249.77	350.98	479.49			
SG-calibrated 52.64±113.93 9.54 12.55 18.71 25.59 42.43 71.73 143.58 0.84 MBP Uncalibrated 146.97±135.89 35.78 44.05 64.70 105.00 173.09 312.64 419.40 99.5 0.84 SG-calibrated 172.19±177.32 39.64 53.59 78.36 119.05 200.04 360.82 495.64 0.91 MEP SG-calibrated 38.00±62.79 5.16 6.26 10.14 18.69 37.64 83.16 147.93 MMMP Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.7 36.15		HMWP	Uncalibrated	60.11 ± 149.69	9.84	12.61	18.40	28.16	47.19	83.31	137.80	1	06:0	< 0.001
MBP Uncalibrated 146.97±135.89 35.78 44.05 64.70 105.00 173.09 312.64 419.40 99.5 0.84 MEP SG-calibrated 172.19±177.32 3.64 53.59 78.36 119.05 20.04 36.08 495.64 0.91 MEP Uncalibrated 32.21±48.12 3.55 5.07 8.71 16.51 34.88 70.92 115.41 99.2 0.91 MMP Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.7 36.15 98.1 0.84			SG-calibrated	52.64±113.93	9.54	12.55	18.71	25.59	42.43	71.73	143.58			
SG-calibrated 172.19±177.32 39.64 53.59 78.36 119.05 200.04 360.82 495.64 Uncalibrated 32.21±48.12 3.55 5.07 8.71 16.51 34.88 70.92 115.41 99.2 0.91 SG-calibrated 38.00±62.79 5.16 6.26 10.14 18.69 37.64 83.16 147.93 Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.57 36.15	Female	MBP	Uncalibrated	146.97±135.89	35.78	44.05	64.70	105.00	173.09	312.64	419.40	99.5	0.84	< 0.001
Uncalibrated 32.21±48.12 3.55 5.07 8.71 16.51 34.88 70.92 115.41 99.2 0.91 SG-calibrated 38.00±62.79 5.16 6.26 10.14 18.69 37.64 83.16 147.93 Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.57 36.15			SG-calibrated	172.19±177.32	39.64	53.59	78.36	119.05	200.04	360.82	495.64			
SG-calibrated 38.00 ± 62.79 5.16 6.26 10.14 18.69 37.64 83.16 147.93 Uncalibrated 12.60 \pm 14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61 \pm 12.67 3.40 5.05 7.19 10.09 15.55 25.57 36.15		MEP	Uncalibrated	32.21±48.12	3.55	5.07	8.71	16.51	34.88	70.92	115.41	99.2	0.91	< 0.001
Uncalibrated 12.60±14.06 2.03 3.12 5.41 9.42 15.00 24.66 33.16 98.1 0.84 SG-calibrated 13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.57 36.15			SG-calibrated	38.00±62.79	5.16	6.26	10.14	18.69	37.64	83.16	147.93			
13.61±12.67 3.40 5.05 7.19 10.09 15.55 25.57		MMP	Uncalibrated	12.60±14.06	2.03	3.12	5.41	9.42	15.00	24.66	33.16	98.1	0.84	< 0.001
			SG-calibrated	13.61 ± 12.67	3.40	5.05	7.19	10.09	15.55	25.57	36.15			

Li et al. BMC Public Health (2025) 25:802 Page 9 of 16

Pvalue < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 r value 3.82 08.0 3.83 0.81 Detected (%) 99.7 495.19 532.74 59.84 32.67 37.69 361.63 404.27 20.48 24.03 245.12 215.44 14.13 153.93 4.94 8.04 8.91 Percentiles 102.88 6.13 5.27 57.67 73.09 3.43 4.40 47.10 59.61 5.48 3.68 7.80 208.01 ± 200.19 78.47±145.77 39.06±116.17 43.59±105.29 14.42 ± 32.89 23.91 ± 59.81 12.98 ± 36.40 21.29±65.71 nean±SD 4.71 ± 16.80 Concentration (ng/mL) SG-calibrated SG-calibrated SG-calibrated SG-calibrated SG-calibrated Uncalibrated **Jncalibrated Jncalibrated Jncalibrated** Uncalibrated Phthalate metabolite Table 2 (continued) MEOHF **HMWP** MEHP LMWP Gender

Discussion

The primary objective of this research was to investigate whether urinary phthalate metabolites were correlated with depressive symptoms among Chinese college students. Our research results indicate that MBP and LMWP were positively correlated with depressive symptoms among college students, and this association only remained for female college students after stratified by gender. Moreover, we further found that insomnia had positive moderating effects on the correlation of MBP and LMWP with depressive symptoms, as well as there were gender differences. This study offers valuable scientific insights that can significantly contribute to the prevention and control of depressive symptoms among college students.

In this study, the rates of mild depression, and moderate depression and above in college students was 31.9% and 9.2%, respectively. Compared with domestic and foreign studies, the rates of mild depression was at a higher level, while moderate depression and above were at a lower level. For example, a study of university students in Spain showed that the rates of mild depression, and moderate depression and above in university students were 7.5% and 10.9%, respectively [54]. Another study of university students in Poland showed that the prevalence of mild depression, and moderate depression and above in university students was 25.1% and 9.6%, respectively [55]. Likewise, a study of Chinese university students showed that the rates of mild depression, and moderate depression and above were 13.8% and 17.3%, respectively [56]. However, another study of 3 891 university students in China showed that the rate of both mild depression (14.8%) and moderate depression and above (7.7%) was lower than that of our study [57]. Meanwhile, we also found that the prevalence of mild depression was higher in females (32.5%) than in males (30.5%), while the prevalence of moderate depression and above was higher in males (10.9%) than in females (8.4%), but the difference was not statistically significant.

Additionally, the results of this study showed that urinary phthalate metabolites were detected in 79.2%~100.0% of study participants. The higher detection rate indicates that Chinese college students have widespread exposure to phthalates. This finding aligns with the results of a study on phthalate exposure among college students in China, which reported a detection rate of 98.0% [58]. While phthalate exposure is widespread among humans, the levels of exposure differ among various populations and even between gender. Several studies have found higher levels of urinary phthalate metabolites in women and non-white ethnic groups [59, 60]. Meanwhile, several studies have also revealed that females exhibit higher concentrations of phthalate metabolites compared to males, potentially attributable

Li et al. BMC Public Health (2025) 25:802 Page 10 of 16




Fig. 1 Heatmap of the correlation of phthalate metabolites, insomnia, with depressive symptoms in college students




Fig. 2 Heatmap of the correlation of phthalate metabolites, insomnia, with depressive symptoms in male college students

Li et al. BMC Public Health (2025) 25:802 Page 11 of 16




Fig. 3 Heatmap of the correlation of phthalate metabolites, insomnia, with depressive symptoms in female college students

to their higher use of personal hygiene products and cosmetics [61, 62]. In fact, studies frequently discover that phthalate metabolites are detectable in 99.0%~100.0% of samples provided by females [63]. However, another study conducted on adults in the United States revealed that males had higher levels of each phthalate metabolites compared to females [64]. In this study, we found that the SG-standardized concentrations (mean) of MBP, MEP, and LMWP was slightly higher in females than in males, while the SG-standardized concentrations (mean) of MMP, MEHP, MEHHP, MEOHP, and HMWP wass lightly higher in males than in females.

At present, there is growing concern about the relationship of phthalate exposure with depressive symptoms. However, current research have focused more on phthalate exposure in the elderly [24, 65] and adult populations [10] and rarely focused on college students. For example, a study of the elderly in Anhui Province, China found that the highest tertiles of MEHP and MBP were positively related to depressive symptoms [24]. Similarly, another study examining the adult population in the United States uncovered positive correlations between MEHHP and mono (2-ethyl-5-carboxypentyl) phthalate (MECPP) and depressive symptoms [10]. However, another survey using the National Health and Nutrition Examination Survey 2005–2008 data suggests no such association [66]. In this study, we found that the MBP

and LMWP were positively correlated with depressive symptoms, and this association only remained for female college students after stratified by gender. One possible explanation is that females use more personal hygiene products and cosmetics, resulting in increased skin sensitivity to phthalate exposure [15, 17], which in turn contributes to the onset of depressive symptoms. Similarly, animal studies have aslo shown that perinatal phthalate exposure increases anxiety-like responses only in adult females mice [22]. However, a study involving 351 mother-child pairs revealed that higher urinary phthalate concentrations during the second trimester of pregnancy were correlated with higher scores for externalization and internalization problems only in boys [67].

Previous studies have suggested that phthalate exposure or sleep problems were risk factors for the development of depressive symptoms [10, 32]. However, the specific role that sleep problems play in the progression of depressive symptoms induced by phthalate exposure remains undiscovered and unexplored. In this survey, we found that insomnia had a positive moderating role on the correlation of MBP and LMWP with depressive symptoms, as well as there were gender differences. Our findings indicate that phthalate exposure may have a potential mechanism for increasing the risk of depressive symptoms through sleep problems. In fact, prior research has established that exposure to phthalates can

Li et al. BMC Public Health (2025) 25:802 Page 12 of 16

Table 3 Association between phthalate metabolites, insomnia, and depressive symptoms by adjusted generalized linear model

Gender	Variable	D	epressive symptom	ıs
		β value	95% CI	Pvalue
Overall	MBP	1.160	0.423 ~ 1.896	0.002
	MEP	0.141	$-0.472 \sim 0.755$	0.652
	MMP	0.144	-0.761 ~ 1.050	0.755
	MEHP	-0.120	-0.477 ~ 0.236	0.507
	MEHHP	0.280	-0.469 ~ 1.030	0.463
	MEOHP	0.070	-0.734 ~ 0.873	0.865
	LMWP	1.230	0.348 ~ 2.113	0.006
	HMWP	0.125	-0.660 ~ 0.910	0.755
	Insomnia	0.656	0.597~0.716	< 0.001
Male	MBP	0.737	-0.611 ~ 2.084	0.284
	MEP	-0.120	-1.239 ~ 0.998	0.833
	MMP	1.786	-0.101 ~ 3.674	0.064
	MEHP	-0.012	-0.677 ~ 0.654	0.973
	MEHHP	-0.319	-1.574 ~ 0.937	0.619
	MEOHP	-0.657	-1.973 ~ 0.658	0.327
	LMWP	0.711	-0.889 ~ 2.312	0.384
	HMWP	-0.459	-1.741 ~ 0.824	0.483
	Insomnia	0.745	0.645 ~ 0.845	< 0.001
Female	MBP	1.320	0.453 ~ 2.187	0.003
	MEP	0.120	-0.610 ~ 0.851	0.747
	MMP	-0.244	-1.258 ~ 0.770	0.637
	MEHP	-0.138	-0.560 ~ 0.284	0.522
	MEHHP	0.452	-0.478 ~ 1.381	0.341
	MEOHP	0.355	-0.654 ~ 1.365	0.490
	LMWP	1.396	0.351 ~ 2.440	0.009
	HMWP	0.325	-0.663 ~ 1.313	0.519
	Insomnia	0.608	0.532~0.684	< 0.001

Note: Model adjusted for age, major, self-reported academic performance, number of friends, paternal education level, self-rated bodily form, sleep quality, smoking, drinking, family history of depression, and hospitalization

cause disruption of circadian rhythms, which in turn can lead to sleep disorders, such as insomnia [29, 68], leading to the onset of depressive symptoms. In addition, studies have demonstrated a correlation between early exposure to phthalates and emotional problems, poorer language development, and reduced mental and psychomotor development, these neurobehavioral traits may share a biological basis with sleep health [27]. At the same time, phthalates are endocrine disrupting chemicals that influence endogenous hormones. Exposure to phthalates not only disrupts neural circuits, but also impedes the maturation of hormone-mediated mechanisms that regulate development and sleep [28], leading to sleep deprivation and depressive symptoms.

Our study has some limitations. Firstly, the crosssectional design, while revealing significant associations, does not establish a definitive causal relationship between phthalate metabolites and depressive symptoms among college students. Secondly, retrospective investigations inevitably involve information bias. To mitigate this, we have implemented rigorous measures to minimize information bias by conducting comprehensive training and evaluation for investigators and conducting anonymous surveys among participants through electronic questionnaires. Thirdly, while many potential confounding factors were considered, we were not able to adjust for all possible covariates in our analysis and potential residual confounding could lead to bias in reported estimates. Fourth, phthalate exposure was estimated based on metabolite concentrations in a single urine sample, which may not represent the average daily exposure level. However, research indicates that single spot-sampling reflects average exposure and moderate sensitivity [67]. Fifth, due to the concentrations of most phthalate metabolites in morning urine samples was significantly higher than in other time periods [69]. Considering the nonpersistent nature of phthalates in vivo and the corresponding variation in phthalate exposure levels, future studies are encouraged to investigate the relationship of phthalate concentrations with mental health outcomes at multiple sampling timepoints. Moreover, future studies can also measure the concentration of phthalate metabolites through blood samples due to the established method (ultra-performance liquid chromatography-mass spectrometry) is accurate and highly sensitive [70]. However, there were also some benefits that should be acknowledged. A notable strength of our study lies in its substantial sample size, which enabled us to conduct a robust examination of the potential correlation between urinary phthalate metabolites and depressive symptoms. Additionally, the population-based design of our study allows us to generalize our findings to a broader group of college students.

Conclusion

Overall, we found that Chinese college students were widely exposed to phthalates. The results of the current study reveal significant cross-sectional associations between MBP, LMWP, and depressive symptoms among college students, and this association only remained for female college students after stratified by gender. Furthermore, we also found that insomnia has a positive moderating role on the correlation of MBP and LMWP with depressive symptoms, as well as there were sex differences. These findings have the potential to inform strategies designed to decrease phthalate exposure and improve both physical and mental health outcomes among college students. Meanwhile, further longitudinal investigations are also imperative to both replicate and expand upon the existing findings.

Li et al. BMC Public Health (2025) 25:802 Page 13 of 16

 Table 4
 The moderating effects of insomnia on the correlation of phthalate metabolites with depressive symptoms

WBP CON				Depleasive symbolins (Overlain)		_	epressives	Depressive symptoms (Male)	ale)	Dep	ressive sym	Depressive symptoms (Female)	<u>e</u>
	Variable	β value	t value	R ² value	F value	β value	t value	R ² value	F value	β value	t value	R ² value	F value
	constant	11.55	4.63**	0.49	61.00**	8.05	2.12*	09:0	29.15**	13.88	3.97**	0.44	34.11**
MBP	_	1.11	3.62**			1.06	1.99*			1.18	3.14*		
ınsı	Insomnia	0.65	21.35**			0.75	14.50**			0.59	15.24**		
MB	MBP×Insomnia	0.21	2.71*			0.17	1.46			0.22	2.12*		
MEP CON	constant	11.16	4.42**	0.48	58.47**	8.37	2.21*	0.61	29.72**	12.93	3.64**	0.43	32.33**
MEP	۵.	0.03	0.12			0.52	1.18			-0.20	-0.61		
sul	Insomnia	0.65	21.36**			92.0	14.72**			0.61	15.39**		
ME	MEP×Insomnia	0.10	1.64			0.26	2.86*			0.01	80.0		
MMP con	constant	10.90	4.33**	0.48	58.41**	7.36	1.96	0.61	30.27**	13.16	3.73**	0.43	32.50**
MMP	1P	0.17	0.45			0.59	0.78			-0.19	-0.43		
ınsı	Insomnia	99.0	21.51**			0.74	14.46**			0.61	15.48**		
NM	MMPxInsomnia	0.13	1.43			0.43	3.21*			-0.17	-1.27		
MEHP	constant	10.63	4.23**	0.48	58.91**	7.17	1.87	0.59	28.27**	12.84	3.64**	0.43	32.71**
ME	MEHP	0.02	0.16			0.02	60.0			0.04	0.24		
)SUI	Insomnia	99.0	21.52**			0.74	14.26**			0.61	15.68**		
ME	MEHP×Insomnia	0.08	2.43*			0.07	1.23			80.0	1.82		
MEHHP	constant	10.94	4.34**	0.48	58.24**	7.41	1.95	09:0	28.68**	13.47	3.82**	0.43	33.11**
ME	MEHHP	0.23	0.74			-0.63	-1.25			69:0	1.71		
)SUI	Insomnia	99.0	21.43**			0.75	14.44**			0.61	15.76**		
ME	MEHHP×Insomnia	90.0	0.75			-0.19	-1.67			0.20	2.03*		
MEOHP	constant	10.92	4.34**	0.48	58.11**	7.48	1.97	09:0	28.84**	13.54	3.83**	0.43	32.83**
MĒ	MEOHP	0.10	0.30			99:0-	-1.27			0.58	1.31		
sul	Insomnia	99:0	21.43**			0.75	14.40**			0.61	15.64**		
MĒ	MEOHP×Insomnia	0.01	0.16			-0.22	-1.89			0.18	1.68		
LMWP	constant	11.70	4.68**	0.49	60.47**	8.49	2.24*	0.61	29.60**	13.97	3.97**	0.44	33.44**
.W.	LMWP	1.13	3.08**			1.30	2.07*			1.12	2.46*		
)SUI	Insomnia	0.65	21.37**			92.0	14.66**			0.59	15.18**		
.W.	LMWP×Insomnia	0.23	2.70*			0.27	2.10*			0.21	1.75		
HMWP	constant	10.92	4.34**	0.48	58.21**	7.52	1.97*	09:0	28.59**	13.41	3.86**	0.43	33.04**
ŽI	HMWP	0.21	0.65			-0.58	-1.14			29.0	1.55		
sul	Insomnia	99:0	21.45**			0.75	14.39**			0.61	15.76**		
ŽĪ.	HMWP×Insomnia	0.05	0.67			-0.18	-1.54			0.21	1.94		

Note: *P<0.05; **P<0.01. Model adjusted for age, major, self-reported academic performance, number of friends, paternal education level, self-rated bodily form, sleep quality, smoking, drinking, family history of depression, and hospitalization

Li et al. BMC Public Health (2025) 25:802 Page 14 of 16

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12889-025-21986-z.

Supplementary Material 1

Acknowledgements

We acknowledge all the participants who participated in this study.

Author contributions

Designed the experiments: Xiaoyan Wu, Fangbiao Tao. Conducted the experiments: Wanyu Che, Yajuan Yang, Shuman Tao. Contributed materials: Tangjun Jiang, Liwei Zou, Shuman Tao. Analyzed the data: Tingting Li. Wrote the essay: Tingting Li.

Funding

This work was supported by the National Natural Science Foundation of China (grant number:82173542, 82373592, 82304169). Grants for Scientific Research Level Improvement Plan from Anhui Medical University (2022xkjT004).

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request (Xiaoyan Wu, xywu@ahmu. edu.cn).

Declarations

Ethics approval and consent to participate

The Ethics Committee of Anhui Medical University approved this study (NO: 20170291). All data procedures were carried out in accordance with relevant ethical guidelines and regulations associated with the declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei 230032, Anhui China

²Department of Ophthalmology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China

³MOE Key Laboratory of Population Health Across Life Cycle, No 81 Meishan Road, Hefei 230032, Anhui, China

⁴Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei 230032, Anhui, China

⁵NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei 230032, Anhui, China ⁶School of Nursing, Anhui Medical University, 15 Feicui Road, Hefei 230601, Anhui, China

Received: 20 December 2024 / Accepted: 17 February 2025 Published online: 27 February 2025

References

- Liu H, Zhang M, Yang Q, Yu B. Gender differences in the influence of social isolation and loneliness on depressive symptoms in college students: a longitudinal study. Soc Psychiatry Psychiatr Epidemiol. 2020;55(2):251–7.
- Akhtar P, Ma L, Waqas A, Naveed S, Li Y, Rahman A, et al. Prevalence of depression among university students in low and middle income countries (LMICs): a systematic review and meta-analysis. J Affect Disord. 2020;274:911–9.
- Gao L, Xie Y, Jia C, Wang W. Prevalence of depression among Chinese university students: a systematic review and meta-analysis. Sci Rep. 2020;10(1):15897.

- Zarowski B, Giokaris D, Green O. Effects of the COVID-19 pandemic on university students' mental health: a literature review. Cureus. 2024;16(2):e54032.
- Chang JJ, Ji Y, Li YH, Pan HF, Su PY. Prevalence of anxiety symptom and depressive symptom among college students during COVID-19 pandemic: a meta-analysis. J Affect Disord. 2021;292:242–54.
- Qu Y, Li T, Xie Y, Tao S, Yang Y, Zou L, et al. Association of chronotype, social jetlag, sleep duration and depressive symptoms in Chinese college students. J Affect Disord. 2023;320:735–41.
- Zhang J, Gu X, Zhang X, Lee J, Chang M, Zhang T. Longitudinal effects of Motivation and physical activity on depressive symptoms among College Students. Int J Environ Res Public Health. 2021;18(10):5121.
- Lemon ED, Vu M, Roche KM, Hall KS, Berg CJ. Depressive symptoms in relation to adverse childhood experiences, discrimination, Hope, and Social Support in a diverse sample of College Students. J Racial Ethn Health Disparities. 2022;9(3):992–1002.
- Lin J, Cheng S, Zhang J, Zhao L, Yuan S, Zhang L, et al. Racial differences in the associations of urinary phthalate metabolites with depression risk. Environ Res. 2023;226:115670.
- Wang CJ, Yang HW, Li MC. Association between phthalate exposure and the risk of depressive symptoms in the adult population of the United States. Chemosphere. 2023;334:139031.
- Zhang YJ, Guo JL, Xue JC, Bai CL, Guo Y. Phthalate metabolites: characterization, toxicities, global distribution, and exposure assessment. Environ Pollut. 2021;291:118106.
- 12. Xu H, Wu X, Liang C, Shen J, Tao S, Wen X, et al. Association of urinary phthalates metabolites concentration with emotional symptoms in Chinese university students. Environ Pollut. 2020;262:114279.
- 13. Eales J, Bethel A, Galloway T, Hopkinson P, Morrissey K, Short RE, et al. Human health impacts of exposure to phthalate plasticizers: an overview of reviews. Environ Int. 2022;158:106903.
- Wong KH, Durrani TS. Exposures to endocrine disrupting chemicals in Consumer Products-A Guide for pediatricians. Curr Probl Pediatr Adolesc Health Care. 2017;47(5):107–18.
- Pagoni A, Arvaniti OS, Kalantzi Ol. Exposure to phthalates from personal care products: urinary levels and predictors of exposure. Environ Res. 2022;212:113194. Pt A).
- Hu L, Mei H, Feng H, Huang Y, Cai X, Xiang F, et al. Exposure to bisphenols, parabens and phthalates during pregnancy and postpartum anxiety and depression symptoms: evidence from women with twin pregnancies. Environ Res. 2023;221:115248.
- Parlett LE, Calafat AM, Swan SH. Women's exposure to phthalates in relation to use of personal care products. J Expo Sci Environ Epidemiol. 2013;23(2):197–206.
- Hatch EE, Nelson JW, Qureshi MM, Weinberg J, Moore LL, Singer M, et al. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. Environ Health. 2008;7:27.
- Kang JS, Baek JH, Song MY, Rehman NU, Chung HJ, Lee DK, et al. Long-term exposure changes the environmentally relevant bis(2-ethylhexyl) phthalate to be a neuro-hazardous substance disrupting neural homeostasis in emotional and cognitive functions. Environ Pollut. 2023;324:121387.
- 20. Sun D, Zhou L, Wang S, Liu T, Zhu J, Jia Y, et al. Correction and republication: Effect of Di-(2-ethylhexyl) phthalate on the hypothalamus-pituitary-thyroid axis in adolescent rat. Endocr J. 2018;65(3):261–8.
- Zuo HX, Li JQ, Han B, Ke CJ, Liu XD, Zhang YC, et al. Di-(n-butyl)-phthalateinduced oxidative stress and depression-like behavior in mice with or without ovalbumin immunization. Biomed Environ Sci. 2014;27(4):268–80.
- Xu X, Yang Y, Wang R, Wang Y, Ruan Q, Lu Y. Perinatal exposure to di-(2-eth-ylhexyl) phthalate affects anxiety- and depression-like behaviors in mice. Chemosphere. 2015;124:22–31.
- Lee KS, Lim YH, Kim KN, Choi YH, Hong YC, Lee N. Urinary phthalate metabolites concentrations and symptoms of depression in an elderly population. Sci Total Environ. 2018;625:1191–7.
- 24. Bao C, Lv J, Chen JR, Wei GZ, Liu N, Wang YT, et al. Chronic inflammation as a potential mediator between phthalate exposure and depressive symptoms. Ecotoxicol Environ Saf. 2022;233:113313.
- 25. Hatcher KM, Smith RL, Li Z, Flaws JA, Davies CR, Mahoney MM. Preliminary findings reveal that phthalate exposure is associated with both subjective and objective measures of sleep in a small population of midlife women. Maturitas. 2022;157:62–5.
- 26. Zamora AN, Peterson KE, Goodrich JM, Téllez-Rojo MM, Song PXK, Meeker JD, et al. Associations between exposure to phthalates, phenols, and parabens

Li et al. BMC Public Health (2025) 25:802 Page 15 of 16

- with objective and subjective measures of sleep health among Mexican women in midlife: a cross-sectional and retrospective analysis. Environ Sci Pollut Res Int. 2023;30(24):65544–57.
- Wu X, Liu S, Wen L, Tan Y, Zeng H, Liang H, et al. Association between phthalates and sleep problems in the U.S. adult females from NHANES 2011–2014. Int J Environ Health Res. 2024;34(4):1961–76.
- Sears CG, Braun JM. Urinary phthalate metabolite concentrations and adolescent sleep duration. Environ Epidemiol. 2021;5(2):e134.
- Kim SS, Lee S, Eghan K, Yoo D, Chun HS, Kim WK. Adverse effects of diethyl
 phthalate and butyl benzyl phthalate on circadian rhythms and sleep patterns in zebrafish larvae. Ecotoxicol Environ Saf. 2024;288:117350.
- Zamora AN, Peterson KE, Téllez-Rojo MM, Song PXK, Meeker JD, Cantoral A, et al. Urinary phthalates, phenols, and parabens in relation to sleep health markers among a cohort of Mexican adolescents. Sci Total Environ. 2023;861:160651.
- Joo HJ, Kwon KA, Shin J, Park S, Jang SI. Association between sleep quality and depressive symptoms. J Affect Disord. 2022;310:258–65.
- Moo-Estrella J, Arankowsky-Sandoval G, Valencia-Flores M. Sleep habits and sleep problems associated with depressive symptoms in school-age children. J Child Adolesc Psychiatr Nurs. 2022;35(2):157–63.
- Hertenstein E, Benz F, Schneider CL, Baglioni C. Insomnia-A risk factor for mental disorders. J Sleep Res. 2023;32(6):e13930.
- Honglv X, Jian T, Jiaxing Y, Yunpeng S, Chuanzhi X, Mengdie H, et al. Mobile phone use addiction, insomnia, and depressive symptoms in adolescents from ethnic minority areas in China: a latent variable mediation model. J Affect Disord. 2023;320:381–9.
- Williams AB, Dzierzewski JM, Griffin SC, Lind MJ, Dick D, Rybarczyk BD. Insomnia disorder and behaviorally Induced Insufficient Sleep Syndrome: prevalence and relationship to Depression in College Students. Behav Sleep Med. 2020;18(2):275–86.
- Ebert DD, Buntrock C, Mortier P, Auerbach R, Weisel KK, Kessler RC, et al. Prediction of major depressive disorder onset in college students. Depress Anxiety. 2019;36(4):294–304.
- AlJameel AH, AlSaleh LS, Bawazir NH, AlOmair AS, Almalki SA. How Mental Health correlates with subjective oral health status: a crosssectional study among a Group of University students. Niger J Clin Pract. 2023;26(11):1716–22.
- 38. Li T, Chen Y, Xie Y, Tao S, Zou L, Yang Y, et al. Moderating effects of PER3 gene DNA methylation on the association between problematic mobile phone use and chronotype among Chinese young adults: focus on gender differences. J Behav Addict. 2024;13(2):554–64.
- 39. Gao H, Zhu YD, Xu YY, Zhang YW, Yao HY, Sheng J, et al. Season-dependent concentrations of urinary phthalate metabolites among Chinese pregnant women: repeated measures analysis. Environ Int. 2017;104:110–7.
- Wang L, Ren J, Chen J, Gao R, Bai B, An H, et al. Lifestyle choices mediate the association between educational attainment and BMI in older adults in China: a cross-sectional study. Front Public Health. 2022;10:1000953.
- Tran VD, Do VV, Pham NM, Nguyen CT, Xuong NT, Jancey J, et al. Validity of the International Physical Activity Questionnaire-Short Form for Application in Asian countries: a study in Vietnam. Eval Health Prof. 2020;43(2):105–9.
- 42. Puciato D, Borysiuk Z, Rozpara M. Quality of life and physical activity in an older working-age population. Clin Interv Aging. 2017;12:1627–34.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
- Liu XC, Tang MQ, Hu L, Wang AZ, Wu HX, Zhao GF, et al. Reliability and validity of the Pittsburgh sleep quality index. Chin J Psychiatry. 1996;2:103–7. Chinese.
- Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Centers for Disease Control and Prevention (CDC). Youth risk behavior surveillance -United States, 2011. MMWR Surveill Summ. 2012;61(4):1–162.
- Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307.
- Chung KF, Kan KK, Yeung WF. Assessing insomnia in adolescents: comparison of Insomnia Severity Index, Athens Insomnia Scale and Sleep Quality Index. Sleep Med. 2011;12(5):463–70.
- 48. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire JAMA. 1999;282(18):1737–44.
- Wang W, Bian Q, Zhao Y, Li X, Wang W, Du J, et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2014;36(5):539–44.

- Zota AR, Phillips CA, Mitro SD. Recent fast food consumption and Bisphenol A and Phthalates exposures among the U.S. Population in NHANES, 2003–2010. Environ Health Perspect. 2016;124(10):1521–8.
- Zota AR, Calafat AM, Woodruff TJ. Temporal trends in phthalate exposures: findings from the National Health and Nutrition Examination Survey, 2001–2010. Environ Health Perspect. 2014;122(3):235–41.
- Zhao S, Li X, Xiang ST, Xie L, Kang R, Li L, et al. Changes in the age-specific body mass index distribution among urban children between 2002 and 2018 in Changsha, China. Transl Pediatr. 2021;10(3):502–9.
- Braun JM, Muckle G, Arbuckle T, Bouchard MF, Fraser WD, Ouellet E, et al. Associations of prenatal urinary bisphenol A concentrations with child behaviors and cognitive abilities. Environ Health Perspect. 2017;125(6):067008.
- Ramón-Arbués E, Gea-Caballero V, Granada-López JM, Juárez-Vela R, Pellicer-García B, Antón-Solanas I. The prevalence of Depression, anxiety and stress and their Associated factors in College Students. Int J Environ Res Public Health. 2020:17(19):7001.
- Lelisho ME, Tareke SA. Prevalence and Associated factors of depressive symptoms among Mizan-Tepi University Students during the COVID-19 pandemic. J Racial Ethn Health Disparities. 2023;10(2):633–43.
- Cheng S, An D, Yao Z, Liu JJ, Ning X, Wong JP, et al. Association between Mental Health Knowledge Level and depressive symptoms among Chinese College students. Int J Environ Res Public Health. 2021;18(4):1850.
- 57. Guo L, Cao J, Cheng P, Shi D, Cao B, Yang G, et al. Moderate-to-severe Depression adversely affects lung function in Chinese College Students. Front Psychol. 2020;11:652.
- Ding S, Zhang Z, Chen Y, Qi W, Zhang Y, Xu Q, et al. Urinary levels of phthalate metabolites and their association with lifestyle behaviors in Chinese adolescents and young adults. Ecotoxicol Environ Saf. 2019;183:109541.
- Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. Urinary levels of seven phthalate metabolites in the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ Health Perspect. 2004;112:331–8.
- Kobrosly RW, Parlett LE, Stahlhut RW, Barrett ES, Swan SH. Socioeconomic factors and phthalate metabolite concentrations among United States women of reproductive age. Environ Res. 2012;115:11–7.
- Huang T, Saxena AR, Isganaitis E, James-Todd T. Gender and racial/ethnic differences in the associations of urinary phthalate metabolites with markers of diabetes risk: National Health and Nutrition Examination Survey 2001–2008. Environ Health. 2014;13(1):6.
- 62. Hsieh CJ, Chang YH, Hu A, Chen ML, Sun CW, Situmorang RF, et al. TMICS study group. Personal care products use and phthalate exposure levels among pregnant women. Sci Total Environ. 2019;648:135–43.
- Chiang C, Pacyga DC, Strakovsky RS, Smith RL, James-Todd T, Williams PL, et al. Urinary phthalate metabolite concentrations and serum hormone levels in pre- and perimenopausal women from the midlife women's Health Study. Environ Int. 2021:156:106633.
- Ghosh R, Haque M, Turner PC, Cruz-Cano R, Dallal CM. Racial and sex differences between urinary phthalates and metabolic syndrome among U.S. adults: NHANES 2005–2014. Int J Environ Res Public Health. 2021;18(13):6870.
- Kim KN, Choi YH, Lim YH, Hong YC. Urinary phthalate metabolites and depression in an elderly population: National Health and Nutrition Examination Survey 2005–2012. Environ Res. 2016;145:61–7.
- Berk M, Williams LJ, Andreazza AC, Pasco JA, Dodd S, Jacka FN, et al. Pop, heavy metal and the blues: secondary analysis of persistent organic pollutants (POP), heavy metals and depressive symptoms in the NHANES National Epidemiological Survey. BMJ Open. 2014;4(7):e005142.
- England-Mason G, Martin JW, MacDonald A, Kinniburgh D, Giesbrecht GF, Letourneau N, et al. Similar names, different results: consistency of the associations between prenatal exposure to phthalates and parent-ratings of behavior problems in preschool children. Environ Int. 2020;142:105892.
- Hatcher KM, Smith RL, Chiang C, Li Z, Flaws JA, Mahoney MM. Association of phthalate exposure and endogenous hormones with self-reported sleep disruptions: results from the midlife women's Health Study. Menopause. 2020;27(11):1251–64.
- Sakhi AK, Sabaredzovic A, Cequier E, Thomsen C. Phthalate metabolites in Norwegian mothers and children: levels, diurnal variation and use of personal care products. Sci Total Environ. 2017;599–600:1984–92.

Li et al. BMC Public Health (2025) 25:802 Page 16 of 16

70. Fan S, Zou J, Xue Y, Liu P, Wu G, Zhao R. Detection method of phthalate esters and their metabolites in blood. Wei Sheng Yan Jiu. 2017;46(2):309–17. Chinese.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.